Apr 20, 2022
Earlier this month, ICER released a white paper titled “The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability.” If you have been monitoring ICER’s work over the years, the paper likely matches your expectations. Ostensibly, the...
Mar 27, 2022
Patients Rising’s first annual Health Plan Heroes event will honor companies that have adopted innovative benefit design for their employees. In addition, a panel of experts will have a roundtable discussion on ways for employers to enhance patient access to...
Mar 16, 2022
In mid-February, ICER released a Final Evidence Report on tirzepatide, a new insulin treatment for Type 2 diabetes (T2D). After following its normal process – including preliminary drafts and public comments – ICER concluded the new medication works better...
Feb 11, 2022
Inconsistency at ICER is nothing new. For years, they have been releasing their own version of proprietary value assessments about new drugs and treatments. They’ve set standard practices and protocols for their assessment process and have updated them over the...
Feb 10, 2022
On February 3, 2022, ICER released its draft evidence report, “Special Assessment of Outpatient Treatments for COVID-19.” This is the most recent step in ICER’s process that is expected to conclude with a public meeting in April and the release of a final report in...
Dec 16, 2021
For years, policymakers across the political spectrum have sought to make the U.S. healthcare system more transparent. Unfortunately, the status quo too often incentivizes policies and practices that seem designed to keep patients in the dark about the real cost of...
